Breaking News Instant updates and real-time market news.

CELG

Celgene

$98.50

-2.13 (-2.12%)

08:02
10/17/16
10/17
08:02
10/17/16
08:02

Celgene: Open-label Touchstone extension study showed symptom improvement

Celgene International Sarl announced that data from the open-label extension of the TOUCHSTONE phase 2 clinical trial of ozanimod in patients with moderate to severe ulcerative colitis are to be presented at the United European Gastroenterology Week in Vienna, Austria and at the American College of Gastroenterology Annual Scientific Meeting in Las Vegas. Ozanimod is an investigational selective S1P 1 and 5 receptor modulator. TOUCHSTONE evaluated the efficacy and safety of 0.5 mg and 1 mg doses of ozanimod compared with placebo after eight weeks of treatment in 197 patients with moderate to severe active ulcerative colitis. Patients who achieved a clinical response at week 8 continued with their original treatment through week 32 in a maintenance phase. The primary endpoint was the proportion of patients in remission at week 8. Secondary endpoints were: the proportion of patients achieving a clinical response, the proportion of patients with mucosal improvement and the change from baseline in Mayo score. Previously reported results showed TOUCHSTONE met its primary endpoint and secondary endpoints with statistical significance for patients on the 1 mg dose of ozanimod versus placebo. TOUCHSTONE participants in all three treatment arms entered the open-label extension if they did not respond to treatment after the induction phase, relapsed during the maintenance phase or completed the maintenance phase The objective of the open-label extension phase is to evaluate the long-term efficacy and safety of daily ozanimod 1 mg. Treatment with ozanimod 1 mg in the extension phase also showed a decrease in the proportion of patients with rectal bleeding and moderate or severe diarrhea. "Findings from this extension study at week 44 showed improvements in efficacy measures for patients who took ozanimod throughout both the blinded study and the extension," said Scott Smith, President, Celgene Inflammation & Immunology. "We recognize the strong need for innovative treatments that help patients with inflammatory bowel disease achieve durable results. We are committed to advancing additional transformational oral treatment options for these patients."

  • 27

    Oct

  • 06

    Nov

CELG Celgene
$98.50

-2.13 (-2.12%)

09/30/16
PIPR
09/30/16
NO CHANGE
Target $25
PIPR
Overweight
Piper's Schimmer found Nektar validation at Celgene event
Piper Jaffray analyst Joshua Schimmer says Celgene's (CELG) analyst event provided "another indirect validation" of Nektar Therapeutics' (NKTR) oncology approach. Celgene surprisingly implicated IL-2 as one of the primary mechanisms of Revlimid, Schimmer tells investors in a research note. He views the development as supporting his "enthusiastic outlook" for NKTR-214, the company's long-acting IL-2 targeting Teffector cells. The analyst reiterates an Overweight rating on Nektar with a $25 price target.
10/14/16
ADAM
10/14/16
NO CHANGE
Target $156
ADAM
Buy
Celgene pipeline broader and stronger than ever, says Canaccord
Canaccord analyst John Newman said Celgene's pipeline is broader and stronger than at any point in its history.He reiterated his Buy rating based on his confidence in the commercial potential for GED-0301 for Crohn's disease, ozanimod in both ulcerative colitis and multiple sclerosis, and continued growth for Otezla. Newman reiterated his $156 price target on Celgene shares.
10/17/16
WELS
10/17/16
NO CHANGE
WELS
Celgene data better than expected, says Wells Fargo
After Celgene announced detailed results from a phase 1b study of oral mogersen in moderate-to severe Crohn's Disease, Wells Fargo says that the results "are better than expected" and leave the company's drug "favorably" positioned relative to approved biologics. The firm says that Celgene's drug "could be positioned as the first highly effective oral for Crohn's Disease," and it keeps an Outperform rating on the stock.
10/17/16
LEER
10/17/16
NO CHANGE
LEER
Market Perform
Celgene data suggests viable drug, says Leerink
Leerink analyst Geoffrey Porges notes that Celgene has announced top-line results from Phase 1b study of GED-301 in Crohn's Disease, and says that absent statistical analyses or a greater insight into participant performance across the study's treatment arms, or longer duration of follow-up, it is difficult to evaluate the full significance of these results. Nonetheless, the analyst believes the drug seems to have some modest efficacy which bodes positively for potential approval as a front-line agent in Crohn's Disease. He reiterates a Market Perform rating on the shares.

TODAY'S FREE FLY STORIES

TLRD

Tailored Brands

$26.39

7.4597 (39.41%)

13:02
12/08/16
12/08
13:02
12/08/16
13:02
Hot Stocks
Tailored Brands surges as Jos. A. Bank turnaround gains traction »

Shares of Tailored Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

GE

General Electric

$31.68

0.08 (0.25%)

13:01
12/08/16
12/08
13:01
12/08/16
13:01
Hot Stocks
GE Transportation acquires Iders Incorporated, terms not disclosed »

GE Transportation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ESRX

Express Scripts

$75.85

-0.88 (-1.15%)

13:01
12/08/16
12/08
13:01
12/08/16
13:01
Periodicals
Citron cautious on Express Scripts, has $45 target on shares »

Citron Research tweeted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSY

Insys Therapeutics

$10.70

-0.54 (-4.80%)

12:57
12/08/16
12/08
12:57
12/08/16
12:57
Hot Stocks
Justice Department arrests former Insys executives, including CEO »

The U.S. Attorney's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBOT

Microbot Medical

$7.75

-0.3 (-3.73%)

12:56
12/08/16
12/08
12:56
12/08/16
12:56
Hot Stocks
Breaking Hot Stocks news story on Microbot Medical »

Greenblock Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$19.39

-0.82 (-4.06%)

12:53
12/08/16
12/08
12:53
12/08/16
12:53
Recommendations
Horizon Pharma analyst commentary  »

BMO cuts Horizon Pharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 14

    Dec

MLSS

Milestone Scientific

$1.77

-0.3254 (-15.50%)

12:51
12/08/16
12/08
12:51
12/08/16
12:51
Hot Stocks
Milestone Scientific: Henry Schein ahead of schedule in The Wand training »

Milestone Scientific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTI

Universal Technical

$3.62

0.37 (11.38%)

12:44
12/08/16
12/08
12:44
12/08/16
12:44
Hot Stocks
Breaking Hot Stocks news story on Universal Technical »

Universal Technical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FEYE

FireEye

$13.61

0.41 (3.11%)

12:40
12/08/16
12/08
12:40
12/08/16
12:40
Options
FireEye calls active »

FireEye calls active. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

12:40
12/08/16
12/08
12:40
12/08/16
12:40
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

UTI

Universal Technical

$3.62

0.37 (11.38%)

12:38
12/08/16
12/08
12:38
12/08/16
12:38
Hot Stocks
Breaking Hot Stocks news story on Universal Technical »

Universal Technical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTI

Universal Technical

$3.62

0.37 (11.38%)

12:38
12/08/16
12/08
12:38
12/08/16
12:38
Hot Stocks
Breaking Hot Stocks news story on Universal Technical »

Universal Technical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNST

Monster Beverage

$44.47

0.1 (0.23%)

12:35
12/08/16
12/08
12:35
12/08/16
12:35
Options
Monster Beverage put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PF

Pinnacle Foods

$51.04

0.58 (1.15%)

12:31
12/08/16
12/08
12:31
12/08/16
12:31
Conference/Events
Pinnacle Foods to hold an investor luncheon »

Investor Luncheon where…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTI

Universal Technical

$3.62

0.37 (11.38%)

12:30
12/08/16
12/08
12:30
12/08/16
12:30
Hot Stocks
Universal Technical: No pending non-public disclosures to account for stock rise »

Universal Technical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:30
12/08/16
12/08
12:30
12/08/16
12:30
General news
U.S. Household net worth rose »

U.S. Household net worth…

SAN

Banco Santander

$5.19

0.1549 (3.07%)

12:25
12/08/16
12/08
12:25
12/08/16
12:25
Options
Banco Santander call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
12/08/16
12/08
12:25
12/08/16
12:25
Conference/Events
Wells Fargo economists hold an analyst/industry conference call »

Chief Economist Silvia,…

TWTR

Twitter

$19.34

-0.14 (-0.72%)

12:21
12/08/16
12/08
12:21
12/08/16
12:21
Periodicals
Spotify cancels talks to acquire SoundCloud, TechCrunch says »

Spotify has pulled out of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIXG

Aixtron

$4.15

0.042 (1.02%)

12:17
12/08/16
12/08
12:17
12/08/16
12:17
Hot Stocks
Fujian Grand Chip cancels Aixtron takeover bid after U.S. intervention »

Grand Chip Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
12/08/16
12/08
12:16
12/08/16
12:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:16
12/08/16
12/08
12:16
12/08/16
12:16
Technical Analysis
NASDAQ market internals summary »

Volume is lighter for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNC

PNC Financial

$114.46

1.79 (1.59%)

12:15
12/08/16
12/08
12:15
12/08/16
12:15
Options
PNC Financial put volume heavy and directionally bearish »

Bearish flow noted in PNC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jan

GOOG

Alphabet

$771.19

12.08 (1.59%)

, GOOGL

Alphabet Class A

$791.47

15.29 (1.97%)

12:12
12/08/16
12/08
12:12
12/08/16
12:12
Hot Stocks
Google enters partnership with Gupshup for Actions on Google Assistant »

Gupshup announced a…

GOOG

Alphabet

$771.19

12.08 (1.59%)

GOOGL

Alphabet Class A

$791.47

15.29 (1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

12:10
12/08/16
12/08
12:10
12/08/16
12:10
General news
U.S. VIX equity volatility is up another 2% to the 12.40 area »

U.S. VIX equity…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.